Recent clinical insights regarding the additive inhibitory effects of midostaurin on AML blasts with mutated FLT3 treated with intensive chemotherapy led us to embark on a randomized phase II clinical trial in older patients with newly diagnosed AML to investigate the additive impact of midostaurin on AML blasts, irrespective of their FLT3 mutational status, treated with 10-day decitabine. The gene discussed is FLT3; the disease is acute myeloid leukemia.